Free Alerts   Login
Health Care › Services-Medical Laboratories

NTRA Stock Price Correlated With Natera Financials

NTRA Stock Price vs. Quarterly
NTRA
Income Statement
Cash Flow
Balance Sheet

NTRA Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

NTRA Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

NTRA Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Vanguard Group
10,971,895 sh
588,147 sh
6%
$687,280
$227,799
JPMorgan Chase
7,954,212 sh
397,420 sh
5%
$498,249
$163,860
Fred Alger Management
7,076,651 sh
120,465 sh
2%
$443,281
$135,470
Blackrock.
6,305,838 sh
552,125 sh
10%
$394,998
$140,396
Samlyn Capital
3,874,801 sh
-525,425 sh
-12%
$242,718
$48,008
Farallon Capital Management
3,474,883 sh
1,197,000 sh
53%
$217,667
$116,871
State Street
3,185,683 sh
207,907 sh
7%
$199,551
$67,784
Alliancebernstein
2,990,416 sh
-94,236 sh
-3%
$187,320
$50,824
Invesco.
2,816,142 sh
286,646 sh
11%
$176,403
$64,473
Rtw Investments, Lp
2,593,323 sh
-58,460 sh
-2%
$162,446
$45,105
Kynam Capital Management
2,400,000 sh
-518,237 sh
-18%
$150,336
-$11,685
Ameriprise Financial
2,283,903 sh
86,713 sh
4%
$143,063
$45,838
Eversept Partners, Lp
2,251,588 sh
-162,199 sh
-7%
$141,039
$23,584
FMR
1,879,329 sh
-184,334 sh
-9%
$117,722
$26,405
American Century Companies
1,870,496 sh
1,870,496 sh
NEW
$117,168
$117,168
Geode Capital Management
1,771,062 sh
127,393 sh
8%
$110,957
$38,212
Principal Financial Group
1,703,615 sh
112,825 sh
7%
$106,715
$36,323
Citadel Advisors
1,663,344 sh
1,654,644 sh
19019%
$104,192
$103,807
Sofinnova Investments.
1,550,280 sh
-1,550,280 sh
-50%
$97,110
-$53,763
Millennium Management
1,520,333 sh
-1,914,321 sh
-56%
$95,234
-$56,749
COMPANY PROFILE
1 . Description of Business ​ Natera, Inc. (the “Company”) was formed in the state of California as Gene Security Network, LLC in November 2003 and incorporated in the state of Delaware in January 2007. The Company is a diagnostics company with proprietary molecular and bioinformatics technology that it is applying to change the management of disease worldwide. The Company’s cell-free DNA (“cfDNA”) technology combines its novel molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell, with its statistical algorithms which incorporate data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with high accuracy and coverage. The Company’s technology has been proven clinically and commercially in the women’s health space, in which it develops and commercializes non- or minimally-invasive tests to evaluate risk for, and thereby enable early detection of, a wide range of genetic conditions, such as Down syndrome. The Company is now translating its success in women’s health and applying its core technology to the oncology market, in which it is commercializing a personalized blood-based DNA test to detect molecular residual disease and monitor disease recurrence, as well as to the organ health market, initially with a test to assess kidney transplants for rejection. The Company operates laboratories certified under the Clinical Laboratory Improvement Amendments ("CLIA") providing a host of cell-free DNA-based molecular testing services. The Company determines its operating segments based on the way it organizes its business to make operating decisions and assess performance. The Company operates one segment, the development and commercialization of molecular testing services, applying its proprietary technology in the fields of women’s health, oncology and organ health. The Company has three subsidiaries. The Company's product offerings include its Panorama Non-Invasive Prenatal Test ("NIPT") that screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother; Vistara, a single-gene mutations screening test performed to identify single-gene disorders; Horizon Carrier Screening ("HCS") to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetics (“Spectrum”) to evaluate embryos to identify chromosomal anomalies or inherited genetic conditions to improve the chances of a healthy pregnancy during an in vitro fertilization ("IVF") cycle; Anora Miscarriage Test (“Anora”) to rapidly and extensively analyze fetal chromosomes to understand the cause of miscarriage; Non-Invasive Paternity Testing (“PAT”), which is exclusively marketed and sold by a licensee from whom the Company receives a royalty; Signatera, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. All testing is available principally in the United States. The Company also offers its Panorama test to customers outside of the United States, primarily in Europe. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch their own tests based on the Company’s technology. Through the third quarter of 2019, the Company offered Evercord for the collection and storage of newborn cord blood and cord tissue units, which was sold in the third quarter of 2019 to a third-party buyer.

Free historical financial statements for Natera Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 32 quarters since 2016. Compare with NTRA stock chart to see long term trends.

Data imported from Natera Inc SEC filings. Check original filings before making any investment decision.